Institute of Biomedical Research of Barcelona
Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
-
Associated Personnel
-
Associated Research Groups
-
Associated Departments
Molecular and Cellular Biomedicine
Read moreOur research is devoted to the study of the molecular mechanisms of cell death and proliferation, as they are involved in the development of different human pathologies.
